# Temple Health – Temple University Health System account plan

> Temple Health is a Philadelphia nonprofit academic health system with $3,294,194K of FY2025 revenue, Temple University Hospital and Fox Chase Cancer Center.

## At a glance

Temple University Health System (Temple Health) is a Pennsylvania nonprofit whose sole member is Temple University. It coordinates hospitals, physician groups and a cancer center in Philadelphia and the surrounding area, including Temple University Hospital, the teaching hospital of the Lewis Katz School of Medicine, and Fox Chase Cancer Center. It serves a disproportionately high number of poor or indigent patients, relying heavily on Medicare, Medicaid and Commonwealth of Pennsylvania support. In FY2025 (year to June 30, 2025) revenues and other support were $3,294,194K and operating income $21,948K. Abhi Rastogi succeeded Michael Young as President and CEO on Jan. 2; the documents give no headcount.

## Business units

- **Temple University Hospital (TUH)** (about 79% of FY2025 revenues before eliminations ($2,598,362K)): An 891-bed acute care teaching hospital at three inpatient campuses plus outpatient locations in Philadelphia and Montgomery Counties, home to the nation's biggest lung transplant centre. Operating income was $22,585K in FY2025; transplants rose 23.4% to 422 across the system.
- **Fox Chase Cancer Center** (about 16% of FY2025 revenues before eliminations): The 100 licensed bed American Oncologic Hospital, the NCI-designated Institute for Cancer Research, the Fox Chase medical group and network. The hospital earned $55,517K of operating income while the research institute lost $44,152K; management puts Fox Chase FY2025 revenue at $1 billion with $130M+ of EBIDA. Robert Uzzo is President and CEO of Fox Chase Cancer Center.
- **Temple Faculty Practice Plan (TFPP)** (about 14% of FY2025 revenues before eliminations ($451,428K)): Provides teaching and physician services to the TUHS hospitals, with net patient service revenue of $284,099K and an operating loss of $1,768K in FY2025.
- **Temple Physicians, Inc. (TPI)** (about 2% of FY2025 revenues before eliminations ($56,522K)): Develops and acquires community-based primary care practices in the service area; operating loss of $10,918K in FY2025.
- **Other subsidiaries**: The T3 critical care air and ground ambulance team, the Bermuda captive TUHS Insurance Company, Temple Center for Population Health and Temple Care (CMS ACO REACH), and Episcopal Hospital outpatient services.
- **Chestnut Hill Hospital**: A 148-bed hospital held 60% and managed by TUHS (equity method, not consolidated); TUHS bought Redeemer Health's 20% stake on August 28, 2025 for a $6,211,000 promissory note. Management reports a significant operational turn-around, with operating income at budget and improved 75% year over year.

## Strategic priorities

- **Workforce stability**: New CEO Abhi Rastogi names stabilising the physician workforce and staff as a first priority.
- **Footprint and access expansion**: Expand Temple's footprint to make it a convenient option for more patients, building on Temple Women & Families Hospital, opened in September 2025, and the Episcopal Campus Crisis Response Center.
- **Clinical service lines**: Grow transplant (led by lung, liver and kidney), cardiology, cancer care at Fox Chase, neurology and urology.
- **Revenue cycle and EPIC optimisation**: Optimise EPIC revenue-cycle technology to reach nine EPIC stars; collections are up $15.0M-$20.0M per month after the fiscal 2024 EPIC implementation.
- **AI, technology and automation**: Use AI and technology where appropriate, including automating scheduling to save labour and improve patient satisfaction and access.
- **Balance sheet and system integration**: The investor presentation's vision: operational performance while strengthening the balance sheet, balanced capital investment, and system integration with the patient always first.

## Latest results

In FY2025 (year to June 30, 2025) revenues and other support rose to $3,294,194K from $2,859,358K, and operating income rose to $21,948K from $973K. Net patient service revenue excluding Commonwealth funding grew $308,177,000, mostly outpatient, "largely driven by performance of the specialty and retail pharmacies", while operating expenses rose $413,861,000, led by supplies and pharmaceuticals and insurance. Net income was $92,141,000 after a $41,992,000 pension settlement charge. Days cash on hand fell to 116 from 124. The statements give no guidance.

## Investments and deals

- **Capital spending**: Purchases of property, plant and equipment were $103,133K in FY2025 (FY2024: $76,516K); capitalised internal-use software totals $88,062K.
- **New facilities**: Temple Women & Families Hospital, an Intermediate Care Unit at TUH-Main and the Episcopal Campus Crisis Response Center all opened in September 2025.
- **Chestnut Hill Hospital stake**: Bought Redeemer Health's 20% interest on August 28, 2025 for a $6,211,000 promissory note at 5% due September 1, 2027, on top of its existing 60% stake.
- **Pension settlement**: Settled the defined benefit plan in FY2025 with $81,729,000 of annuity purchases, triggering a $41,992,000 charge.

## Challenges and risks

- **Medicaid cuts and public funding**: More than 40% of patients admitted to Temple University Hospital are on Medicaid, as hospitals prepare for major Medicaid cuts; Commonwealth support of $564,048K is not guaranteed to continue.
- **Drug and supply costs**: Supplies and pharmaceuticals rose to $836,852K from $672,000K on outpatient infusion and pharmacy volumes; Jefferson Health Plan losses of $15.2M came largely from GLP-1 costs.
- **Professional liability**: Insurance expense rose to $124,861K from $80,515K as old professional liability cases were settled; the discounted liability was $273,592K.
- **Thin operating margin**: Operating income of $21,948K on $3,294,194K of revenue, with operating cash flow falling to $35,917K from $98,886K.

## What leadership says

> "Mike has left us in a position of strategic growth and financial stability. We want to continue that" — Abhi Rastogi, President and CEO, The Philadelphia Inquirer, 30 October 2025

> "Not all of our patient populations could adapt to it, but where it's applicable, we need to make it easier for them to get access to the care" — Abhi Rastogi, President and CEO, The Philadelphia Inquirer, 30 October 2025, on AI and technology


## Where a supplier can help

- **Patient access and scheduling automation**: Tied to the AI and automation priority: automated scheduling to save labour and improve access is an explicit initiative.
- **Revenue-cycle optimisation on EPIC**: Tied to the revenue cycle priority: the goal of nine EPIC stars and dependence on Medicare and Medicaid audits favour billing, denials and collections tools.
- **Pharmacy and drug-cost management**: Tied to the drug and supply cost challenge: rising pharmaceutical spend, GLP-1 costs and the 340B programme make pharmacy analytics relevant.
- **Workforce and staffing solutions**: Tied to the workforce stability priority and higher nursing pay rates: retention, scheduling and staffing tools fit the new CEO's agenda.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Temple University Health System Consolidated Financial Statements, years ended June 30, 2025 and 2024 (audited)](https://tuhsfinance.templehealth.org/AUDITED%20FINANCIALS/FY%202025%20TUHS%20Audited%20Financial%20Statements.pdf)

Annual report · 2025-10-27

- Temple University Health System (TUHS, "Temple Health") is a Pennsylvania nonprofit whose sole member is Temple University; it coordinates hospitals, physician groups and a cancer center in Philadelphia and the surrounding area, and Temple University Hospital (TUH) is the teaching hospital of the Lewis Katz School of Medicine.
- FY2025 (year to June 30, 2025): revenues and other support of $3,294,194K (FY2024: $2,859,358K); net patient service revenue $3,185,989K (FY2024: $2,775,358K); operating income $21,948K versus $973K; excess of revenues over expenses $92,141K versus $79,001K.
- Heavy dependence on public payers and state support: Commonwealth of Pennsylvania support recognised in revenue was $564,048K (FY2024: $483,614K), with provider tax expense of $89,890K; the notes say "There is no guarantee that this funding will continue in future years."
- Main cost pressures: supplies and pharmaceuticals rose to $836,852K from $672,000K, insurance to $124,861K from $80,515K (net medical professional liability expense $117,756K vs $75,447K), salaries were $1,322,227K.
- Business units: Temple University Hospital (891 beds at three inpatient campuses) is about 79% of revenues before eliminations (computed); Fox Chase Cancer Center entities (the 100-licensed-bed American Oncologic Hospital, the NCI-designated Institute for Cancer Research, the Fox Chase medical group) about 16% (computed); the Temple Faculty Practice Plan, Temple Physicians, the T3 transport team, a Bermuda captive insurer and an ACO REACH entity complete the system.
- Capital: purchases of property, plant and equipment $103,133K (FY2024: $76,516K); long-term debt $378,193K, mainly 2017 and 2022 hospital revenue bonds; $100,000,000 revolving line of credit with $25,000,000 drawn.
- Chestnut Hill Hospital (148 beds) is held 60% and run by TUHS; on August 28, 2025 TUHS bought Redeemer Health's 20% stake for a $6,211,000 promissory note.
- The defined benefit pension plan was settled in FY2025 (annuities of $81,729,000 purchased, settlement charge of $41,992,000); Deloitte issued an unmodified opinion dated October 27, 2025.

### [TUHS Year-End Report (Investor Quarterly Report), year ended June 30, 2025 (unaudited)](https://tuhsfinance.templehealth.org/CURRENT%20STATEMENTS/TUHS%20Investor%20Quarterly%20Report%20-%20June%2030,%202025.pdf)

Interim report

- The most recent quarterly disclosure on TUHS's own investor site: the unaudited year-end report for the year ended June 30, 2025.
- Net income $92,141,000 versus $79,001,000; operating income $21,948,000 versus $973,000, driven by higher net patient service revenue.
- Net patient service revenue excluding Commonwealth funding rose by $308,177,000: outpatient +$249,864,000, "largely driven by performance of the specialty and retail pharmacies", inpatient +$41,476,000 on higher acuity and transplant volumes; Commonwealth funding +$57,033,000.
- Operating expenses rose $413,861,000: supplies and pharmaceuticals +$164,852,000 (outpatient infusion and pharmacy), salaries +$86,737,000 (nursing pay rates), insurance +$44,346,000 (professional liability claims).
- Volumes: 37,244 inpatient discharges (-0.6%), case mix index 2.00, 422 transplants (+23.4%), 150,791 ED visits (-5.7%), 928,304 physician visits (+3.7%).
- Payor mix by discharge: Medicare 43%, Medicaid 39% (both including managed care), Blue Cross 10%.
- Days cash on hand 116 versus 124; obligated group debt $379.8 million versus $399.4 million.

### [TUHS Annual Investor Conference Call presentation, year ending June 30, 2025](https://tuhsfinance.templehealth.org/INVESTOR%20RELATIONS/TUHS%20FY25%20Annual%20Investor%20Call%20Presentation.pdf)

Report · 2025-11-19

- Slides of the November 19, 2025 bondholder call, presented by CEO Michael Young, CFO Jerry Oetzel, Chief Accounting Officer Michael DiFranco and TUH CEO Abhi Rastogi; no transcript is published.
- Abhi Rastogi was named the next President and CEO of Temple Health; John Ryan becomes Chief Administrative Officer as well as EVP and General Counsel.
- FY2025 operating income including Chestnut Hill was $5.6M better than budget; patient revenue grew 10% versus budget and 14% versus the prior year, with 340B pharmacy performance up 60% year over year.
- Revenue cycle: collections up $15.0M-$20.0M per month, recovering the $23M EPIC reserve from FY23.
- Headwinds: $15.2M of losses on Jefferson Health Plan (pharmacy spend, largely GLP-1 costs); insurance expense 113% over budget and 49% over the prior year from the deliberate settlement of old professional liability cases.
- Fox Chase Cancer Center FY2025 revenue reached $1 billion with $130M+ of EBIDA, against $350M of annual revenue in FY2011.
- Openings in September 2025: Temple Women & Families Hospital, an Intermediate Care Unit at TUH-Main and the Episcopal Campus Crisis Response Center; transplant growth led by lung, liver and kidney.

### [Abhi Rastogi will succeed Mike Young as CEO of Temple Health (The Philadelphia Inquirer)](https://www.inquirer.com/health/temple-health-abhi-rastogi-ceo-mike-young-20251030.html)

Executive talk · Abhi Rastogi, President and CEO-designate of Temple Health (COO of Temple Health and CEO of Temple University Hospital) · 2025-10-30

- Temple University president John Fry named COO Abhi Rastogi, at Temple for 23 years, to succeed Michael Young as CEO of Temple Health on Jan. 2; Young retires after seven years at Temple.
- The article puts Temple's growth under Young at $1.9 billion to $3.3 billion of annual revenue, with two hospitals added (Chestnut Hill and Temple Women & Families) and lower long-term debt.
- Rastogi takes over as hospitals prepare for major Medicaid cuts. More than 40% of patients admitted to Temple University Hospital are on Medicaid.
- His stated priorities: stabilising the physician workforce and staff, expanding Temple's footprint to make it a convenient option for more patients, and using AI and technology where appropriate.
- He will build on lung transplant (the nation's biggest centre), cardiology, cancer care at Fox Chase Cancer Center, neurology and urology: "Mike has left us in a position of strategic growth and financial stability. We want to continue that".
- He led the conversion of the former Cancer Treatment Centers of America site into Temple Women & Families, the Episcopal emergency department and crisis response centre expansion, and the integration of Chestnut Hill Hospital.
- Young stays as a consultant for two years, on the health system board for two years and on the Fox Chase board for at least a year.

## Questions about Temple Health – Temple University Health System

### What is Temple University Health System?

A Philadelphia nonprofit academic health system owned by Temple University, running Temple University Hospital, Fox Chase Cancer Center, physician groups and other subsidiaries.

### What was Temple Health's revenue in FY2025?

Revenues and other support were $3,294,194K in the year to June 30, 2025, with operating income of $21,948K.

### Who leads Temple Health?

Abhi Rastogi, at Temple for 23 years, succeeded Michael Young as President and CEO on Jan. 2; Jerry Oetzel is CFO.

### What are Temple Health's priorities?

Workforce stability, expanding its footprint and access, growing transplant, cardiology, cancer, neurology and urology, optimising the EPIC revenue cycle, and using AI where appropriate.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
